Presentation Will be Webcast Wednesday, January 14, 2004
SAN DIEGO, Jan. 12 /PRNewswire-FirstCall/ -- Neurocrine Biosciences, Inc.
(Nasdaq: NBIX) announced today that the Company will be presenting at the
JPMorgan Healthcare Conference in San Francisco at the Westin St. Francis
Hotel on Wednesday afternoon, January 14, 2004 at 4:00PM Pacific Standard Time
and 7:00PM Eastern Standard Time. The presentation will be simultaneously
webcast and can be accessed on the Company's website at
http://www.neurocrine.com or via JPMorgan's website at
Gary Lyons, President and CEO of Neurocrine will present the Company's
clinical development program for indiplon for the treatment of insomnia and
will also provide an update on the Company's broad development pipeline and
research programs. If you are unable to attend the webcast and would like
further information on this announcement please contact the Investor Relations
Department at Neurocrine Biosciences at (858) 658-7600 and ask for Claudia
Jones or Elizabeth Foster.
Upon connecting to the website link, look for the heading "Webcast," click
on 22nd Annual Healthcare Conference where you will be directed to register
for the conference. If you attend the live webcast, click on "Live Webcasts"
located the left side of the screen and select Neurocrine. If you attend at a
later time, click on the "On-Demand Webcasts" on the left side of the screen
and select Neurocrine. The replay will be available approximately 24 hours
after the live webcast and will be archived until Thursday, January 29, 2004.
Viewers are encouraged to visit either website approximately 5 minutes prior
to the presentation to download or install any necessary audio software.
Neurocrine Biosciences, Inc. is a product-based biopharmaceutical company
focused on neurological and endocrine diseases and disorders. Our product
candidates address some of the largest pharmaceutical markets in the world
including insomnia, certain female and male disorders, anxiety, depression,
diabetes, multiple sclerosis, irritable bowel syndrome, eating disorders,
pain, and autoimmunity. Neurocrine Biosciences, Inc. news releases are
available through the Company's website via the Internet at
SOURCE Neurocrine Biosciences, Inc.